Here’s what you should know.
1. The compound inhibits adenylyl cyclases enzymes responses.
2. The compound differs from opioids because it selectively represses only adenylyl cyclases enzymes. It is the only compound that selectively represses enzymes.
3. Val Watts, PhD, led the researchers responsible for identifying the compound.
4. Researchers tested the compound in a positive trial. Dr. Watts said the team is being held back because of funding troubles.
5. Dr. Watts believes if the compound reaches drug testing phases, the medical community will receive it warmly. The response to-date has been positive.
More articles on anesthesia:
Want to hone your intubation training? There’s an app for that
AHCA could increase anesthesiologists’ number of uninsured patients: 3 fast facts
Dr. Mary Craddock named in ‘Leading Physicians of the World’ — 3 fast facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.